Sacubitril/Valsartan (S/V) was proven to significantly modify the clinical course of patients with heart failure with reduced ejection fraction (HFrEF), improving symptoms, outcomes and functional capacity as a consequence of cardiac reverse remodeling (RR) (1–7). Studies on S/V induced RR focused on volumetric changes and improvement of cardiac function in terms of ejection fraction. This approach fails to describe the complex effects of S/V on cardiovascular (CV) physiopathology. Data on intraventricular pressure gradients (IVPGs) distribution are missing and those on vascular properties changes are frequently limited to hypertensive cohorts. The aim of our study was to evaluate both cardiac and vascular remodeling in a group of HFrEF patients after 6 months of therapy with S/V, in terms of volumes, contractility, IVPGs distribution, vascular properties and ventricular-arterial coupling.

Cardiac and vascular remodeling after 6 months of therapy with sacubitril/valsartan. mechanistic insights from advanced echocardiographic analysis / Monosilio, Sara; Filomena, Domenico; Luongo, Federico; Sannino, Michele; Cimino, Sara; Neccia, Matteo; Mariani, Marco Valerio; Birtolo, Lucia Ilaria; Benedetti, Giulia; Tonti, Giovanni; Pedrizzetti, Gianni; Vizza, Carmine Dario; Maestrini, Viviana; Agati, Luciano. - In: FRONTIERS IN CARDIOVASCULAR MEDICINE. - ISSN 2297-055X. - 9:(2022). [10.3389/fcvm.2022.883769]

Cardiac and vascular remodeling after 6 months of therapy with sacubitril/valsartan. mechanistic insights from advanced echocardiographic analysis

Monosilio, Sara;Filomena, Domenico;Luongo, Federico;Sannino, Michele;Cimino, Sara;Neccia, Matteo;Mariani, Marco Valerio;Birtolo, Lucia Ilaria;Benedetti, Giulia;Vizza, Carmine Dario;Maestrini, Viviana;Agati, Luciano
2022

Abstract

Sacubitril/Valsartan (S/V) was proven to significantly modify the clinical course of patients with heart failure with reduced ejection fraction (HFrEF), improving symptoms, outcomes and functional capacity as a consequence of cardiac reverse remodeling (RR) (1–7). Studies on S/V induced RR focused on volumetric changes and improvement of cardiac function in terms of ejection fraction. This approach fails to describe the complex effects of S/V on cardiovascular (CV) physiopathology. Data on intraventricular pressure gradients (IVPGs) distribution are missing and those on vascular properties changes are frequently limited to hypertensive cohorts. The aim of our study was to evaluate both cardiac and vascular remodeling in a group of HFrEF patients after 6 months of therapy with S/V, in terms of volumes, contractility, IVPGs distribution, vascular properties and ventricular-arterial coupling.
2022
cardiac; vascular; remodeling; therapy; sacubitril; valsartan: echocardiographic
01 Pubblicazione su rivista::01a Articolo in rivista
Cardiac and vascular remodeling after 6 months of therapy with sacubitril/valsartan. mechanistic insights from advanced echocardiographic analysis / Monosilio, Sara; Filomena, Domenico; Luongo, Federico; Sannino, Michele; Cimino, Sara; Neccia, Matteo; Mariani, Marco Valerio; Birtolo, Lucia Ilaria; Benedetti, Giulia; Tonti, Giovanni; Pedrizzetti, Gianni; Vizza, Carmine Dario; Maestrini, Viviana; Agati, Luciano. - In: FRONTIERS IN CARDIOVASCULAR MEDICINE. - ISSN 2297-055X. - 9:(2022). [10.3389/fcvm.2022.883769]
File allegati a questo prodotto
File Dimensione Formato  
Monosilio_Cardiac_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 916.9 kB
Formato Adobe PDF
916.9 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1635316
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact